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Abstract
Background: BRCA1 and BRCA2 mutation carriers are at sub-
stantially increased risk for developing breast and ovarian cancer.
The incomplete penetrance coupled with the variable age at diag-
nosis in carriers of the same mutation suggests the existence of
genetic and nongenetic modifying factors. In this study, we evalu-
ated the putative role of variants inmany candidate modiﬁer genes.
Methods: Genotyping data from 15,252 BRCA1 and 8,211
BRCA2 mutation carriers, for known variants (n ¼ 3,248) located
within or around 445 candidate genes, were available through the
iCOGS custom-designed array. Breast and ovarian cancer associa-
tion analysis was performedwithin a retrospective cohort approach.
Results: The observed P values of association ranged between
0.005 and 1.000. None of the variants was signiﬁcantly associated
with breast or ovarian cancer risk in either BRCA1 or BRCA2
mutation carriers, after multiple testing adjustments.
Conclusion: There is little evidence that any of the evaluated
candidate variants act asmodiﬁers of breast and/or ovarian cancer
risk in BRCA1 or BRCA2 mutation carriers.
Impact: Genome-wide association studies have been more
successful at identifying genetic modiﬁers of BRCA1/2 penetrance
than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1);
308–16. 2014 AACR.
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Introduction
Germline BRCA1 or BRCA2 mutations substantially increase
the risk of developing breast and ovarian cancer over those of
the general population (1). The penetrance is incomplete and
combined with the observed variability in age at cancer diag-
nosis in carriers of identical mutations, suggests the existence of
genetic and/or environmental modifying factors. Direct evi-
dence for genetic modiﬁers of breast and ovarian cancer risk for
BRCA1 and BRCA2 mutation carriers has been provided
through genome-wide association studies (GWAS; ref. 2). In
parallel, multiple variants in candidate genes that affect BRCA1
or BRCA2 protein expression, act along the same biologic
pathways, or physically interact with BRCA1 or BRCA2 proteins
have been evaluated as putative modiﬁers of BRCA1/2 muta-
tions (reviewed in ref. 3). However, only a handful of these
factors were conﬁrmed and independently validated as "true
modiﬁers" (4). The aim of the present study was to assess the
putative modiﬁer effect of 3,248 sequence alterations in 445
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Table 1. Description of the 17 projects included in the study
Project Rationale for testing SNPs as risk modiﬁers for breast
cancer and ovarian cancer in BRCA-mutation carriers
Number of
SNPs included
Reference
1 Previous data suggested that irradiation response genes
whose expression is associated with BRCA1 and BRCA2
mutation status are enriched for the presence of common
genetic modiﬁers of breast cancer risk.
18 Walker LC et al. Evidence for SMAD3 as amodiﬁer of breast cancer risk
in BRCA2 mutation carriers. Breast Cancer Res 2010;12:R102.
2 X chromosome SNPs shown to be associated with risk of
breast cancer in the CGEMS breast cancer study were
considered.
11 Hunter DJ et al. A genome-wide association study identiﬁes alleles in
FGFR2 associated with risk of sporadic postmenopausal breast
cancer. Nat Genet 2007;39:870–4.
3 Previous data suggested that the "del" allele of rs3834129was
associated with increased breast cancer risk in BRCA1-
mutation carriers.
1 Catucci I et al. The CASP8 rs3834129 polymorphism and breast cancer
risk in BRCA1 mutation carriers. Breast Cancer Res Treat
2011;125:855–60.
4 Search for riskmodiﬁers ofBRCA1 5382insC-mutation carriers
wasperformedby apooledGWAS in 124womendiagnosed
with breast cancer (<45 years) and 119 unaffected controls
(>50 years at last follow-up) from Poland. The highest-
ranked SNPs from the pooled GWAS were selected.
137 None
5 The proposed SNPs are related to genes in regulatory T-cell
(Treg) and myeloid-derived suppressor cell (MDSC)
pathways. Both pathways play a role in cancer
immunosuppression.
2,637 Schreiber RD et al. Cancer immunoediting: integrating immunity's
roles in cancer suppression and promotion. Science
2011;331:1565–70.
6 The proposed SNPs were associated with breast density.
These SNPs were tested only as modiﬁer of breast cancer
risk.
72 Steude JS et al. Mammographic density and matrix
metalloproteinases in breast tissue. Cancer Microenviron
2010;3:57–65. Guo YP et al. Growth factors and stromal matrix
proteins associated with mammographic densities. Cancer
Epidemiol Biomarkers Prev 2001;10:243–8. Verheus M et al.
Common genetic variation in the IGF-1 gene, serum IGF-I levels and
breast density. Breast Cancer Res Treat 2008;112:109–22. Diorio C
et al. Genetic polymorphisms involved in insulin-like growth factor
(IGF) pathway in relation to mammographic breast density and IGF
levels. Cancer Epidemiol Biomarkers Prev 2008;17:880–8. Diorio C
et al. Vitamin D pathway polymorphisms in relation to
mammographic breast density. Cancer Epidemiol Biomarkers Prev
2008;17:2505–8.
7 SNPs or (SNPs in) genes were considered according to
following criteria: (i) affecting circadian rhythms;
(ii) interacting with CLOCK; (iii) involved in binding IGF-I to
binding proteins; (iv) in progesterone receptor gene and
previously found associated with BC and OvC risk;
(v) related to disease treatment.
20 Hoffman AE et al. CLOCK in breast tumorigenesis: genetic,
epigenetic, and transcriptional proﬁling analyses. Cancer Res
2010;70:1459–68. Kelemen LE et al. Genetic variation in stromal
proteins decorin and lumican with breast cancer: investigations
in two case-control studies. Breast Cancer Res 2008;10:R98.
Patel AV et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms
predict circulating IGF levels but not breast cancer risk: ﬁndings
from the Breast and Prostate Cancer Cohort Consortium (BPC3).
PLoS One. 2008;3:e2578.
8 All these SNPs are located in selenoprotein genes and are
involved in selenium metabolism; selenium is known to be
associated with cancer risk.
11 Oestergaard MZ et al. Interactions between genes involved in the
antioxidant defence system and breast cancer risk. Br J Cancer
2006;95:525–31. Meplan C et al. Association between
Polymorphisms in Glutathione Peroxidase and Selenoprotein P
Genes, Glutathione Peroxidase Activity, HRT Use and Breast
Cancer Risk PLoS One. 2013;8:e73316. Udler M et al. Common
germline genetic variation in antioxidant defense genes and
survival after diagnosis of breast cancer. J Clin Oncol
2007;25:3015–23. Sutherland A et al. Polymorphisms in the
selenoprotein S and 15-kDa selenoprotein genes are associated
with altered susceptibility to colorectal cancer. Genes Nutr
2010;5:215–23.
9 Previous data suggested that the rs1045485 SNP modiﬁed
disease penetrance of breast and ovarian cancer in BRCA1
mutation carriers.
1 Engel C et al. Association of the variants CASP8 D302H and CASP10
V410I with breast and ovarian cancer risk in BRCA1 and BRCA2
mutation carriers. Cancer Epidemiol Biomarkers Prev
2010;19:2859–68.
10 The proposed SNPs are located within the PARP1 gene that
plays a key role in the repair of DNA single-strand breaks.
3 Gonc¸alves A et al. Poly(ADP-ribose) polymerase-1 mRNA expression
in human breast cancer: a meta-analysis. Breast Cancer Res Treat
2011;127:273–81.
11 SNPs were considered because of observations based on
evidences of recent positive selection and presence in the
same genomic region of genes, (i) coding for BRCA1
interacting proteins; (ii) involved in cancer or breast cancer;
(iii) involved in DNA damage response and interacting with
TP53.
13 Voight BF et al. A map of recent positive selection in the human
genome. PLoS Biol 2006; 4:e72. Lappalainen T et al. Genomic
landscape of positive natural selection in Northern European
populations. Eur J Hum Genet 2010;18:471–8.
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candidate genes on breast/ovarian cancer risk in 23,463 BRCA1
and BRCA2 mutation carriers.
Materials and Methods
Recruitment and data collection
All study participants were women, >18 years old, carrying a
deleterious germline mutation in either BRCA1 or BRCA2. DNA
samples and phenotypic data were submitted by 54 study
centers participating in the Consortium of Investigators of
Modiﬁers of BRCA1/2 (CIMBA; ref. 5). Recruitment strategies,
clinical, demographic, and phenotypic data collected from each
participant, and quality control procedures, have previously
been reported (4, 5). All study participants took part in research
studies at the parent institutions under ethically approved pro-
tocols as detailed (4, 5).
Sequence variants genotyped
DNA samples were genotyped using the custom Illumina
iCOGS array which included 211,155 SNPs as previously
described (http://www.nature.com/icogs/primer/cogs-project-
and-design-of-the-icogs-array/; ref. 6). We report results from
3,248 SNPs from 445 candidate genes proposed by 17 PIs
(¼ projects). The rationale for selecting the SNPs or genes as
candidate cancer risk modiﬁers in BRCA1 and BRCA2 mutation
carriers is shown in Table 1. The list of SNPs included in the
study and their gene location (if any) are provided in Supple-
mentary Table S1. Genotyping quality control procedures were
carried out as reported elsewhere (6).
Statistical analysis
Associations were evaluated within a retrospective cohort
framework, by modeling the retrospective likelihood of the
observed genotypes conditional on the disease phenotypes
(4, 7). The associations between genotype and breast or ovarian
cancer risk were assessed using the 1 d.f. score test statistic based
on this retrospective likelihood while accounting for the non-
independence among related individuals (8). All analyses were
stratiﬁed by country of residence and used calendar-year and
cohort-speciﬁc breast and ovarian cancer incidence rates for
BRCA1 and BRCA2 mutation carriers. Details are provided else-
where (2).
Results
A total of 23,463 mutation carriers were included (15,252
BRCA1, 8,211 BRCA2 carriers), 12,127 with breast cancer
(7,797 BRCA1, 4,330 BRCA2 carriers), 3,093 with ovarian cancer
(2,462BRCA1, 631BRCA2 carriers), and9,220 cancer-free carriers
(5,788 BRCA1, 3,432 BRCA2 carriers). All 3,248 SNPs were tested
as genetic risk modiﬁers for both breast and ovarian cancer in
BRCA1 and BRCA2 mutation carriers depending on the selection
rationale (Table 1). For each SNP, the number of individuals with
genotype data, minor allele frequencies, values of the c2 score test
statistic, approximateHR estimates based on the score test statistic
(7), overall P values, and retrospective likelihoodHRare shown in
Supplementary Table S2. Because project 12 was based on the
hypothesis that estrogens contribute to breast cancer pathogen-
esis, these 139 SNPs were stratiﬁed by somatic estrogen receptor
Table 1. Description of the 17 projects included in the study (Cont'd )
Project Rationale for testing SNPs as risk modiﬁers for breast
cancer and ovarian cancer in BRCA-mutation carriers
Number of
SNPs included
Reference
12 Steroid hormones such as estrogens play an important role in
the etiology of breast cancer contributing to tumor growth
by promoting cell proliferation. SNPs in candidate genes
involved in sex steroid metabolism were considered. The
SNPs were tested also as breast cancer risk modiﬁers
considering estrogen receptor status of BRCA-mutation
carriers (see Supplementary Table S3).
139 Labrie F et al. Endocrine and intracrine sources of androgens in
women: inhibition of breast cancer and other roles of androgens
and their precursor dehydroepiandrosterone. Endocr Rev
2003;24:152–82.
13 RAD51C is a breast cancer gene. SNPs located within, or in
close proximity to RAD51C were selected.
17 Meindl A et al. Germline mutations in breast and ovarian cancer
pedigrees establish RAD51C as a human cancer susceptibility gene.
Nat Genet 2010;42:410–4.
14 The highest-ranked SNPs from a GWAS based on 700
hereditary breast cancer cases and 1,200 controls were
selected.
142 None
15 SNP rs2981582 in FGFR2 is strongly associated with risk of
breast cancer and acting as a risk modiﬁer in BRCA2
mutation carriers. Rs2981582 may also inﬂuence the risk of
ovarian cancer among BRCA1/2-mutation carriers. This
SNP was tested only as modiﬁer of ovarian cancer risk.
1 Easton DF et al. Genome-wide association study identiﬁes novel
breast cancer susceptibility loci. Nature 2007;447(7148):1087–93.
Hunter DJ et al. A genome-wide association study identiﬁes alleles
in FGFR2 associated with risk of sporadic postmenopausal breast
cancer. Nat Genet 2007;39: 870–4. Antoniou AC et al. Common
breast cancer predisposition alleles are associated with breast
cancer risk in BRCA1 andBRCA2mutation carriers. Am JHumGenet
2008;82:937–48.
16 The rs10895068 SNP in the promoter of the progesterone
receptor (PR) gene (þ331G/A) has been reported to be
associated with endometrial cancer risk. Our previous
study in 220 patients from BC and OC families showed a
marginal association of the þ331A allele with OC risk. This
SNP was tested only as modiﬁer of ovarian cancer risk.
1 Vivo ID et al. A functional polymorphism in the promoter of the
progesterone receptor gene associated with endometrial cancer
risk. Proc Natl Acad Sci U S A 2002;99:12263–68. Romano A et al.
Impact of two functional progesterone receptor polymorphisms
(PRP):þ331G/A and PROGINS on the cancer risks in familial breast/
ovarian cancer. Open Cancer J 2007;1:1–8.
17 The proposed SNPs were selected according to the
hypothesis that different levels of expression of the
remaining normal allele in BRCA2mutation carriers may be
associated with variable penetrance of BRCA2 mutations.
24 Maia AT et al. Effects of BRCA2 cis-regulation in normal breast and
cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res
2012;14:R63.
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status (Supplementary Table S3).None of the SNPs tested showed
signiﬁcant evidence of association with breast and/or ovarian
cancer risk, as a single tested variant or after adjusting for mutiple
testing. Indeed, there were fewer associations at a nominal P <
0.05 or P < 0.01 than would be expected by chance (Table 2).
Discussion
In this study, there were no discernible effects for the genotyped
SNPs on either breast or ovarian cancer risk in BRCA1 or BRCA2
mutation carriers. Despite the lack of evidence of association
between these speciﬁc variants and breast/ovarian cancer risk for
BRCA1/BRCA2 mutation carriers, these genes may still modify
cancer risk by other sequence alterations that are not represented
on the iCOGS platform, by epigenetic alterations in gene expres-
sion, or in combination and interaction with other polymorph-
isms, that in concert have an overall effect on cancer risk.
In conclusion, the genotyped SNPs in the candidate modiﬁer
genes evaluatedherehavenomajor role inbreast or ovarian cancer
risk modiﬁcation in either BRCA1 or BRCA2 mutation carriers.
Our results suggest that a candidate gene approach where the
selected SNPs have little a priori biologic plausibility is of limited
value in identifying modiﬁer genes, unlike agnostic genome-wide
associations which have beenmore successful (8). Applyingmore
advanced technologies (whole-exome/genome sequencing) and
targeting phenotypically distinct mutation carriers may also offer
further insights into modiﬁer genes' identity.
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aNot all the 3,248 SNPs were tested in each category/tumor group.
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